Literature DB >> 8580799

Determination by interphase-FISH of the clonality of aberrant karyotypes in human hematopoietic neoplasias.

E Gebhart1, T Liehr, P Harrer, S Reichardt, G Schmitt, K Thoma, M Gramatzki, U Trautmann.   

Abstract

Interphase-FISH (fluorescence in situ hybridization) studies have been devoted to the determination of clonality of aberrant karyotypes in human leukemia. Various levels of its extent have been examined, including the meaning of a single aberrant karyotype as representing a microclone, the use of FISH to confirm clonality in bi- or multiclonal leukemia, the estimation of the residual (aberrant) clone after contrasexual bone marrow transplantation, and the redetectability in interphase of the abl/bcr rearrangement. The quantitative findings of all these lines of interphase FISH analyses were based on the comparison with data from a large-scale "control" study on normal cells using the same DNA probes which have been chosen for the determination of clonality, i.e. centromeric DNA probes for chromosomes #1, #3, from #6 to #12, from #15 to #18, #20, X and Y, and a specific probe for the abl/bcr rearrangement. In addition, the validity of interphase-FISH analysis on classical bone marrow smears was examined. As a common outcome it was concluded that interphase-FISH technique is a valuable tool for defining clonality of karyotypic changes and, as a consequence, yields additional prognostic information in many human leukemias. It is recommended to perform interphase FISH in routine cytogenetics of leukemia, whenever reasonable.

Entities:  

Mesh:

Year:  1995        PMID: 8580799     DOI: 10.3109/10428199509056835

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

1.  Somatic mosaicism in cases with small supernumerary marker chromosomes.

Authors:  Thomas Liehr; Tatyana Karamysheva; Martina Merkas; Lukrecija Brecevic; Ahmed B Hamid; Elisabeth Ewers; Kristin Mrasek; Nadezda Kosyakova; Anja Weise
Journal:  Curr Genomics       Date:  2010-09       Impact factor: 2.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.